Biomarkers are measurable indicators that can be used to identify the presence or severity of a disease. In the case of solid tumors, biomarkers are particularly important as they can help identify patients who are most likely to benefit from a particular treatment. The development of new biomarkers is therefore a key driver of growth in the solid tumors treatment market.

Recent advances in biomarker development have led to the identification of new targets for treatment, including mutations in specific genes that are associated with solid tumors. This has led to the development of targeted therapies that can selectively attack cancer cells while sparing healthy tissue. Additionally, the use of liquid biopsies, which involve the analysis of circulating tumor DNA, is enabling physicians to monitor disease progression and treatment response in real-time.

Read More:

https://cmitoc.blogspot.com/2023/04/increasing-cancer-cases-in-world-to.html